Bars

Category: Suggested Reading

All Podcast Categories
S4-22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

S4-22 – PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.

May 22, 2023
S4-20.5 - Harnessing the Strengths of the Patient Advocate Community

S4-20.5 – Harnessing the Strengths of the Patient Advocate Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This final conversation elaborates on the myriad abilities possessed by the patient community which can be deployed to the fight against Fatty Liver diseases.

May 14, 2023
S4-20.3 - Generating and Promoting the Data to Demonstrate Patient Needs

S4-20.3 – Generating and Promoting the Data to Demonstrate Patient Needs

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This conversation focuses around what’s required to recruit all stakeholders to recognize the reality of this disease for patients and their needs.

May 13, 2023
S4-20.2 - Listening to Both Sides: Allied Health for Patient Empowerment

S4-20.2 – Listening to Both Sides: Allied Health for Patient Empowerment

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. In this conversation, Louise Campbell expands on the critical role of nurses as advocates with the unique ability to bridge the patient-physician gaps.

May 13, 2023
S4-20.1 - Who is going to be the Larry Kramer of NASH?

S4-20.1 – Who is going to be the Larry Kramer of NASH?

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This introductory conversation features an impactful statement from Donna on the gravity surrounding these milestone moments and why patient inputs should be held paramount.

May 13, 2023
S4-20 - Leveraging Patient Voice and Needs in the NASH Community

S4-20 – Leveraging Patient Voice and Needs in the NASH Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. Among other topics, the panelists comment on the recent draft report from ICER, the landscape of nomenclature consensus and, generally, how to absorb different perspectives into a common discussion while giving each the weight that they deserve.

May 11, 2023
S4-19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

S4-19.5 – Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this final conversation, each describes the most important thing they would like ICER to learn before another NASH drug analysis.

May 7, 2023
S4-19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-19.4 – Patient Advocates Describe the Reasoning Behind Their Testimonies

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.

May 7, 2023
S4-19.3 - The Role of Biopsy in Prescribing NASH Therapeutics

S4-19.3 – The Role of Biopsy in Prescribing NASH Therapeutics

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group discusses the role of biopsy, drug trial endpoints and more.

May 6, 2023

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Apple Spotify Youtube Soundcloud
More Episodes
Log In
Stay In Touch
Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME